An experimental cancer drug has shown promising success, apparently curing all the patients involved in its trial.
The drug, called dostarlimab, may provide a cure for a form of rectal cancer with 100% of the 18 participants seemingly overcoming the condition with minimal side effects.
The participants received the drug every three weeks for six months for the study which was carried out by Memorial Sloan Kettering Cancer Center (MSKCC), the Mirror reports.